COVID-19 in the fall raises increased concern over the potential for global drug shortages, a team out of Lawson Health Research Institute in London, Ont., is launching “the largest trial of its kind” looking into whether IV sedatives can be replaced with inhaled sedatives.The study — co-led by Dr.
Marat Slessarev with Lawson and Dr. Angela Jerath of Sunnybrook Health Sciences Centre in Toronto — focuses on outcomes related to the use of inhaled sedatives in COVID-19 patients requiring ventilation.
London, Ont., researchers the first to profile immune response to COVID-19 “When COVID-19 patients develop severe respiratory failure and need to be ventilated, they require sedation.